title: Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis.
abstract: Thymus and activation-regulated chemokine (TARC/CCL17) is a member of the T-helper 2 chemokine family. In Japan, serum TARC level has been commercially measured since 2008. After years of experience, we realized that TARC is an extremely useful clinical biomarker for atopic dermatitis (AD) treatment. Usually, physicians conduct a visual examination to determine whether their treatment has been successful; however, the visual examination results may not always be accurate; in such cases, serum TARC levels should be measured to eliminate any ambiguity regarding the treatment outcome. When the waning and waxing of eczema and fluctuations in the serum TARC levels were considered, we frequently found that AD does not follow a natural course but follows non-regulated inflammatory floating caused by insufficient intermittent topical treatment. Serum TARC is a promising biomarker for remission and can be used for accurately monitoring proactive treatment for long-term control. Abnormally high serum TARC levels indicate accelerated pathogenesis of cutaneous inflammation. Rapid normalization and maintaining normal serum TARC levels using appropriate topical treatment is a reasonable strategy for alleviating inflammation without upregulating cytokine expression. Observing serum TARC levels during early intervention for severe infantile AD is worthwhile to determine initial disease activity and evaluate treatment efficacy. Appropriate control of severe early-onset infantile AD is important for improving prognosis of eczema and for preventing food allergies. Additionally, this biomarker is useful for improving patient adherence. Dermatologists will be able to make great progress in treating AD by adopting biomarkers such as TARC for accurately assessing non-visible subclinical disorders.
authors.affiliation: Dermatology, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino, Osaka, Japan.
authors.forename: Yoko
authors.initials: Y
authors.lastname: Kataoka
mesh_terms: D015415:Biomarkers / Q000097:blood; D054414:Chemokine CCL17 / Q000097:blood*; D003876:Dermatitis, Atopic / Q000097:blood* / Q000628:therapy; D006801:Humans; D017063:Outcome Assessment, Health Care
chemical_list: D015415:Biomarkers; C106230:CCL17 protein, human; D054414:Chemokine CCL17
keywords: atopic dermatitis; biomarker; outcome; proactive therapy; thymus and activation-regulated chemokine